The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 11, 2020
Filed:
Feb. 18, 2015
Applicant:
Health Research, Inc., Buffalo, NY (US);
Inventor:
Yasmin Thanavala, Williamsville, NY (US);
Assignee:
Health Research, Inc., Buffalo, NY (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/85 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 31/44 (2006.01); A61K 45/06 (2006.01); A61K 35/15 (2015.01); A61P 35/00 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2818 (2013.01); A61K 31/44 (2013.01); A61K 35/15 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); G01N 33/57438 (2013.01); C07K 2317/76 (2013.01); G01N 2333/70521 (2013.01);
Abstract
Provided are methods and compositions for a combination therapy for liver disorders such as hepatocellular carcinoma. Also provided is a method for determining the effectiveness of therapy involving tyrosine kinase inhibitors such as sorafenib. The method comprises determining the status of PD-1 on T cells, and based on a change in the level of PD-1 on certain cells, a determination of the effectiveness of the tyrosine kinase, and an indication for a combination therapy comprising a lower dose of tyrosine kinase inhibitor and a PD-1 inhibitor can be made.